Skip to content

Advertising disclosure: We earn commissions from some of the products we link to. It never changes our scores or what we publish. Read the full disclosure

Tom’s Weight LossRankings
CompoundedNot tested · not scored

InjectCo

InjectCo

InjectCo publishes compounded semaglutide from $249/month against brand-name costs of $900-$1,400, and unusually sets out financing through CareCredit or Cherry that reduces the monthly payment to around $150, plus HSA and FSA guidance.

Sources captured · researched by Tom

Medications offered

As listed on the provider’s own site. Whether a product is FDA-approved or compounded is the single most important distinction here — we explain why.

  • Compounded semaglutideCompounded · not FDA-approved

What they publish

InjectCo publishes 3 of 12 standard terms. Fields marked “not publicly disclosed” were not stated on the pages we captured, and we have not filled those gaps with assumptions. Compare disclosure across providers

Membership / programme fee
Compounded semaglutide programme published from $249/month; brand-name published at $900-$1,400/month without insurance as comparison (as published)
Medication cost
States financing through CareCredit or Cherry lowers the payment to around $150/month (as published)
Introductory offer
Not publicly disclosed on the pages we captured.
Insurance
Not publicly disclosed on the pages we captured.
HSA / FSA
Publishes guidance on using HSA and FSA funds for semaglutide, describing the effective cost reduction.
Consultation process
Not publicly disclosed on the pages we captured.
Eligibility
Not publicly disclosed on the pages we captured.
Lab work
Not publicly disclosed on the pages we captured.
Pharmacy fulfilment
Not publicly disclosed on the pages we captured.
Shipping
Not publicly disclosed on the pages we captured.
Support services
Not publicly disclosed on the pages we captured.
Cancellation
Not publicly disclosed on the pages we captured.
Refunds
Not publicly disclosed on the pages we captured.

What stands out

  • Publishing medical financing options (CareCredit, Cherry) is rare here, and genuinely relevant given the cost of this treatment.
  • Financing spreads the cost but does not reduce it — the $150 figure is a payment, not a price, and interest terms matter.
  • The HSA/FSA guidance is useful; whether a compounded product qualifies is worth confirming with your plan administrator.

Questions to ask before you pay

These are things we could not settle from published pages, or that we think are easy to misread. Get answers in writing.

  • Financing is borrowing. Check the interest rate and total repayable, not just the monthly figure.
  • Confirm with your HSA/FSA administrator that compounded medication qualifies.
  • Ask which pharmacy compounds it and whether it is 503A or 503B.

Limitations

  • Compounded only.
  • Financing adds cost over time.

Sources

Captured . Pages change — check the current version before relying on anything here.

Worth comparing against

Brand-nameCompoundedInsurance support

Mochi Health

Mochi Health

Flat membership with medication billed separately, and clear on-page compounding disclosure

Membership
from $79/mo
Medication
Billed separately
Publishes7/12 terms
Compounded

Orderly Meds

Orderly Meds

The lowest published entry price here — and a four-fold step up afterwards

Membership
from $74/mo
Medication
Included
Publishes1/12 terms
Insurance support

Sina Medical Care

Sina Medical Care

Direct primary care publishing dedicated HSA guidance and an employer package

Membership
Not published
Medication
Not published
Publishes2/12 terms